Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVISE-AF: Rivaroxaban 15mg vs 20mg in Non-valvular Atrial Fibrillation
NCT06187311Phase 4Recruiting
- Sponsor
- Korea University Anam Hospital
- Start
- Jan 2023
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rivaroxaban in Atrial fibrillation (AFib) (2 arms), sponsored by Korea University Anam Hospital. Primary endpoint: Incident rate of major bleeding events at 12 months. Started Jan 2023; status: recruiting.
02
Drugs
rivaroxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT06187311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06187311.